[
1. Phelan AL, Katz R, Gostin LO. The Novel Coronavirus Originating in Wuhan, China: Challenges for Global Health Governance. JAMA. 2020;323(8):709-10.10.1001/jama.2020.109731999307
]Search in Google Scholar
[
2. Al-Malkey MK, Al-Sammak MA. Incidence of the COVID-19 in Iraq – Implications for travellers. Travel Med Infect Dis. 2020;38:101739.10.1016/j.tmaid.2020.101739721936332405265
]Search in Google Scholar
[
3. WHO; 2021. [https://covid19.who.int/] (access: 04 June 2021)
]Search in Google Scholar
[
4. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061-9.10.1001/jama.2020.1585704288132031570
]Search in Google Scholar
[
5. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020;323(20):2052-9.10.1001/jama.2020.6775717762932320003
]Search in Google Scholar
[
6. Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic treatments for Coronavirus Disease 2019 (COVID-19): A review. JAMA. 2020;323(18):1824-36.10.1001/jama.2020.601932282022
]Search in Google Scholar
[
7. Bajwah S, Wilcock A, Towers R, Costantini M, Bausewein C, Simon ST, et al. Managing the supportive care needs of those affected by COVID-19. Eur Respir J. 2020;55(4):2000815.10.1183/13993003.00815-2020714426832269090
]Search in Google Scholar
[
8. Campos DM de O, Fulco UL, de Oliveira CBS, Oliveira JIN. SARSCoV-2 virus infection: Targets and antiviral pharmacological strategies. J Evid Based Med. 2020;13(4):255-60.10.1111/jebm.12414767531533058394
]Search in Google Scholar
[
9. Sahebnasagh A, Avan R, Saghafi F, Mojtahedzadeh M, Sadremomtaz A, Arasteh O, et al. Pharmacological treatments of COVID-19. Pharmacol Rep. 2020;72:1446-78.10.1007/s43440-020-00152-9743963932816200
]Search in Google Scholar
[
10. Chappell L, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, et al. Dexamethasone in hospitalized patients with COVID-19 – preliminary report. N Engl J Med. 2021;384(8):693-704.10.1056/NEJMoa2021436738359532678530
]Search in Google Scholar
[
11. Kewan T, Covut F, Al-Jaghbeer MJ, Rose L, Gopalakrishna KV, Akbik B. Tocilizumab for treatment of patients with severe COVID-19: A retrospective cohort study. E Clinical Medicine. 2020;24:100418.10.1016/j.eclinm.2020.100418730550532766537
]Search in Google Scholar
[
12. WHO; 2021.[https://www.who.int/] (access: 28 June 2021)
]Search in Google Scholar
[
13. Best JH, Kong AM, Kaplan-Lewis E, Brawley OW, Baden R, Zazzali JL, et al. Treatment patterns in US patients hospitalized with COVID-19 and pulmonary involvement. J Med Virol. 2021;93:5367-75.10.1002/jmv.27049
]Search in Google Scholar
[
14. Chibber P, Haq SA, Ahmed I, Andrabi NI, Singh G. Advances in the possible treatment of COVID-19: A review. Eur J Pharmacol. 2020;883:173372.10.1016/j.ejphar.2020.173372
]Search in Google Scholar
[
15. Lin KJ, Schneeweiss S, Tesfaye H, D’Andrea E, Liu J, Lii J, et al. Pharmacotherapy for hospitalized patients with COVID-19: Treatment patterns by disease severity. Drugs. 2020;80(18):1961-72.10.1007/s40265-020-01424-7
]Search in Google Scholar
[
16. Centers for Disease Control and Prevention. Guidance for COVID-19. [https://www.cdc.gov/coronavirus/2019-ncov/communication/guidance.html] (access: 27 June 0 2021).
]Search in Google Scholar
[
17. Watanabe JH, Kwon J, Nan B, Abeles SR, Jia S, Mehta SR. Medication use patterns in hospitalized patients with COVID-19 in California During the pandemic. JAMA Netw Open. 2021;4(5):e2110775.10.1001/jamanetworkopen.2021.10775
]Search in Google Scholar
[
18. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the treatment of COVID-19 – Final Report. N Engl J Med. 2020;383(19):1813-26.10.1056/NEJMoa2007764
]Search in Google Scholar
[
19. Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395(10236):1569-78.10.1016/S0140-6736(20)31022-9
]Search in Google Scholar
[
20. Rattanaumpawan P, Jirajariyavej S, Lerdlamyong K, Palavutitotai N, Saiyarin J. Real-world experience with favipiravir for treatment of COVID-19 in Thailand: Results from a multi-center observational study. MedRxiv. 2020. [https://doi.org/10.1101/2020.06.24.20133249]10.1101/2020.06.24.20133249
]Search in Google Scholar
[
21. Salazar E, Christensen PA, Graviss EA, Nguyen DT, Castillo B, Chen J, et al. Treatment of Coronavirus Disease 2019 patients with convalescent plasma reveals a signal of significantly decreased mortality. Am J Pathol. 2020;190(11):2290-303.10.1016/j.ajpath.2020.08.001741790132795424
]Search in Google Scholar
[
22. Alsharidah S, Ayed M, Ameen RM, Alhuraish F, Rouheldeen NA, Alshammari FR, et al. COVID-19 convalescent plasma treatment of moderate and severe cases of SARS-CoV-2 infection: A multicenter interventional study. Int J Infect Dis. 2021;103:439-46.10.1016/j.ijid.2020.11.198771777233285283
]Search in Google Scholar
[
23. Arshad S, Kilgore P, Chaudhry ZS, Jacobsen G, Wang DD, Huitsing K, et al. Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19. Int J Infect Dis. 2020;97:396-403.10.1016/j.ijid.2020.06.099733057432623082
]Search in Google Scholar
[
24. Freedberg DE, Conigliaro J, Wang TC, Tracey KJ, Callahan MV, Abrams JA, et al. Famotidine use is associated with improved clinical outcomes in hospitalized COVID-19 patients: A propensity score matched retrospective cohort study. Gastroenterol. 2020;159(3):1129-31.e3.10.1053/j.gastro.2020.05.053724219132446698
]Search in Google Scholar
[
25. Padhy BM, Mohanty RR, Das S, Meher BR. Therapeutic potential of ivermectin as add on treatment in COVID 19: A systematic review and meta-analysis. J Pharm Pharm Sci. 2020;23:462-9.10.18433/jpps3145733227231
]Search in Google Scholar
[
26. Zanasi A, Mazzolini M, Kantar A. A reappraisal of the mucoactive activity and clinical efficacy of bromhexine. Multidiscip Respir Med. 2017;12(1):1-14.10.1186/s40248-017-0088-1535981728331610
]Search in Google Scholar